Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Type 2 Diabetes Mellitus
NCT06982859Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of retatrutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Total Clamp Disposition Index at Week 28. Started Jun 2025; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06982859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982859.